Application and Assessment of Deep Learning for the Generation of
Potential NMDA Receptor Antagonists
- URL: http://arxiv.org/abs/2003.14360v1
- Date: Tue, 31 Mar 2020 16:41:18 GMT
- Title: Application and Assessment of Deep Learning for the Generation of
Potential NMDA Receptor Antagonists
- Authors: Katherine J. Schultz, Sean M. Colby, Yasemin Yesiltepe, Jamie R.
Nu\~nez, Monee Y. McGrady, Ryan R. Renslow
- Abstract summary: Uncompetitive antagonists of the N-methyl D-aspartate receptor (NMDAR) have demonstrated therapeutic benefit in the treatment of neurological diseases such as Parkinson's and Alzheimer's.
Some also cause dissociative effects that have led to the synthesis of illicit drugs.
The ability to generate NMDAR antagonists in silico is therefore desirable both for new medication development and for preempting and identifying new designer drugs.
- Score: 0.0
- License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
- Abstract: Uncompetitive antagonists of the N-methyl D-aspartate receptor (NMDAR) have
demonstrated therapeutic benefit in the treatment of neurological diseases such
as Parkinson's and Alzheimer's, but some also cause dissociative effects that
have led to the synthesis of illicit drugs. The ability to generate NMDAR
antagonists in silico is therefore desirable both for new medication
development and for preempting and identifying new designer drugs. Recently,
generative deep learning models have been applied to de novo drug design as a
means to expand the amount of chemical space that can be explored for potential
drug-like compounds. In this study, we assess the application of a generative
model to the NMDAR to achieve two primary objectives: (i) the creation and
release of a comprehensive library of experimentally validated NMDAR
phencyclidine (PCP) site antagonists to assist the drug discovery community and
(ii) an analysis of both the advantages conferred by applying such generative
artificial intelligence models to drug design and the current limitations of
the approach. We apply, and provide source code for, a variety of ligand- and
structure-based assessment techniques used in standard drug discovery analyses
to the deep learning-generated compounds. We present twelve candidate
antagonists that are not available in existing chemical databases to provide an
example of what this type of workflow can achieve, though synthesis and
experimental validation of these compounds is still required.
Related papers
- Regressor-free Molecule Generation to Support Drug Response Prediction [83.25894107956735]
Conditional generation based on the target IC50 score can obtain a more effective sampling space.
Regressor-free guidance combines a diffusion model's score estimation with a regression controller model's gradient based on number labels.
arXiv Detail & Related papers (2024-05-23T13:22:17Z) - Multi-objective generative AI for designing novel brain-targeting small molecules [0.20088541799100385]
We use multi-objective generative AI to synthesize drug-like BBB-permeable small molecules.
Specifically, we computationally synthesize molecules with predicted binding affinity against dopamine receptor D2.
We design a library of 26,581 novel and diverse small molecules containing hits with high predicted BBB permeability and favorable predicted safety and toxicity profiles.
arXiv Detail & Related papers (2024-04-16T12:57:06Z) - Multiscale Topology in Interactomic Network: From Transcriptome to
Antiaddiction Drug Repurposing [0.3683202928838613]
The escalating drug addiction crisis in the United States underscores the urgent need for innovative therapeutic strategies.
This study embarked on an innovative and rigorous strategy to unearth potential drug repurposing candidates for opioid and cocaine addiction treatment.
arXiv Detail & Related papers (2023-12-03T04:01:38Z) - Zero-shot Learning of Drug Response Prediction for Preclinical Drug
Screening [38.94493676651818]
We propose a zero-shot learning solution for the.
task in preclinical drug screening.
Specifically, we propose a Multi-branch Multi-Source Domain Adaptation Test Enhancement Plug-in, called MSDA.
arXiv Detail & Related papers (2023-10-05T05:55:41Z) - NeuroCADR: Drug Repurposing to Reveal Novel Anti-Epileptic Drug
Candidates Through an Integrated Computational Approach [0.0]
Drug repurposing is an emerging approach for drug discovery involving the reassignment of existing drugs for novel purposes.
A proposed algorithm is NeuroCADR, a novel system for drug repurposing via a multi-pronged approach consisting of k-nearest neighbor algorithms (KNN), random forest classification, and decision trees.
Data was sourced from several databases consisting of interactions between diseases, symptoms, genes, and affiliated drug molecules, which were then compiled into datasets expressed in binary.
NeuroCADR identified novel drug candidates for epilepsy that can be further approved through clinical trials.
arXiv Detail & Related papers (2023-09-04T03:21:43Z) - A clustering and graph deep learning-based framework for COVID-19 drug
repurposing [0.3359875577705538]
This study presents a novel unsupervised machine learning framework that utilizes a graph-based autoencoder for multi-feature type clustering on heterogeneous drug data.
The dataset consists of 438 drugs, of which 224 are under clinical trials for COVID-19.
Our framework relies on reported drug data, including its pharmacological properties, chemical/physical properties, interaction with the host, and efficacy in different publicly available COVID-19 assays.
arXiv Detail & Related papers (2023-06-24T15:00:47Z) - Knowledge-Driven New Drug Recommendation [88.35607943144261]
We develop a drug-dependent multi-phenotype few-shot learner to bridge the gap between existing and new drugs.
EDGE eliminates the false-negative supervision signal using an external drug-disease knowledge base.
Results show that EDGE achieves 7.3% improvement on the ROC-AUC score over the best baseline.
arXiv Detail & Related papers (2022-10-11T16:07:52Z) - Tailoring Molecules for Protein Pockets: a Transformer-based Generative
Solution for Structured-based Drug Design [133.1268990638971]
De novo drug design based on the structure of a target protein can provide novel drug candidates.
We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
arXiv Detail & Related papers (2022-08-30T09:32:39Z) - SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity
Prediction [127.43571146741984]
Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery.
wet experiments remain the most reliable method, but they are time-consuming and resource-intensive.
Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue.
We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
arXiv Detail & Related papers (2022-06-20T14:53:25Z) - Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs.
In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
arXiv Detail & Related papers (2022-02-08T09:42:08Z) - SafeDrug: Dual Molecular Graph Encoders for Safe Drug Recommendations [59.590084937600764]
We propose a DDI-controllable drug recommendation model named SafeDrug to leverage drugs' molecule structures and model DDIs explicitly.
On a benchmark dataset, our SafeDrug is relatively shown to reduce DDI by 19.43% and improves 2.88% on Jaccard similarity between recommended and actually prescribed drug combinations over previous approaches.
arXiv Detail & Related papers (2021-05-05T00:20:48Z)
This list is automatically generated from the titles and abstracts of the papers in this site.
This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.